Giving neurons a new life to fight Parkinson's

We share this report on Parkinson's disease and its advances published by The Conversation

Parkinson's disease affects more than ten million people in the worldThis is a neurodegenerative disorder in which some brain neurons progressively die. These affected cells are located in a region called the substantia nigra and have a key function: producing dopamine, a molecule essential for control movementWhen these neurons disappear, the most well-known symptoms arise, such as tremors, muscle rigidity, slowness, and difficulty walking.

For decades, treatments have focused on compensating for the loss of dopamine in the brain. While it is true that drugs such as Levodopa can significantly improve symptomsThey have a limitation: they do not stop the disease or recover lost neurons. 

In other words, the focus is on addressing the consequences of the problem (dopamine loss), but not its root cause (neuron death). A new strategy is beginning to change that approach. Instead of simply compensating for the damage, it attempts to repair it.

What if we could replace neurons?

Cell therapy is based on a surprisingly simple concept. If Parkinson's destroys the neurons that produce dopamine, why not replace them with new ones?

For years this idea was more of a dream than a real possibility. Neurons are extremely complex. It's not enough to introduce just any cell into the brain: they must be the right type, survive the transplant, integrate into the neural circuits, and produce dopamine in a controlled manner.

The major breakthrough came with the development of induced pluripotent stem cells (iPSCs). These were described by the research group led by the Japanese scientist. Shinya Yamanaka, who received the Nobel Prize in Physiology or Medicine in 2012 for this work.

iPSCs are obtained by reprogramming adult cells, such as skin cells, to return them to an embryonic-like state. From there, they can become many cell types, including dopamine-producing neurons. Thanks to this technology, the idea of ​​replacing neurons is no longer science fiction.

Two clinical trials that mark a turning point

They were published in the magazine in 2025 Nature two pioneering clinical trials that have brought this strategy to the human brain.

In one of them Researchers transplanted dopamine-producing neurons derived from induced pluripotent stem cells into Parkinson's patients. The study showed that the procedure was safe and that the implanted cells could survive for extended periods and produce dopamine in the human brain.

The second essay It used neurons derived from human embryonic cells (hES). Again, the results indicated good tolerability and showed signs of lasting clinical benefit.

What has been observed in the patients?

Although it is still too early to draw definitive conclusions, the studies have shown several promising results:

• The transplanted cells survive in the brain.
• They produce dopamine in a detectable way.
• Some patients show improvement in their motor symptoms.
• No serious short-term safety problems have been observed.

This does not mean that the therapy is ready for general clinical use, but it does mean that the approach is biologically viable.

Why is this advance so important?

Parkinson's disease is a progressive neurodegenerative disorder. Over time, neuronal loss continues, and current treatments become less effective. Cell therapy could offer several key advantages:

1. Act on the cause of the problem, not just on its consequences.
2. Restore the natural production of dopamine instead of administering it externally.
3. To provide lasting benefits, potentially for years.

But it's not a cure yet.

It is important to maintain realistic expectations: these advances do not mean that a cure is already available.

The trials conducted so far include few patients, and follow-up is still limited. It is necessary to verify that the transplanted cells survive for many years and that the benefits are sustained over time.

Furthermore, not all Parkinson's patients are the same. The disease progresses differently in each person, and it is still unclear who will benefit most from a transplant.

Finally, Parkinson's is a complex disease that, over time, affects more systems than just the dopamine-producing neurons. Replacing these cells could greatly improve motor symptoms, but it probably won't resolve all aspects of the disease.

A long but promising road

Despite the limitations, these trials represent a historic milestone. For the first time, the scientific community has clinical evidence that replacing dopamine-producing neurons in humans is feasible and potentially beneficial.

Cell therapy is still in its early stages, but it points in a clear direction. The path involves moving from purely symptomatic treatments toward strategies capable of repairing the brain.

For millions of people living with Parkinson's disease, this road is still long. But, for the first time in decades, the question is no longer whether we can try to rebuild lost neurons, but when and in which patients it can be done safely and effectively.

Source: The Conversation